tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immutep Advances Oncology Trials with Promising Results

Story Highlights
Immutep Advances Oncology Trials with Promising Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Immutep Ltd ( (AU:IMM) ).

Immutep Limited has reported significant progress in its oncology programs, particularly with the TACTI-004 Phase III trial for non-small cell lung cancer (NSCLC), which is expanding across numerous clinical sites globally. The company has achieved promising results in its INSIGHT-003 trial, showing high response and disease control rates in NSCLC patients. Additionally, Immutep’s combination therapy has demonstrated a strong median overall survival in head and neck cancer patients, potentially positioning the company for further regulatory discussions and market opportunities.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a clinical-stage biotechnology company focused on developing novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company is actively involved in advancing its pipeline, particularly in oncology, with a strong emphasis on lung cancer and head and neck cancer treatments.

Average Trading Volume: 3,476,994

Technical Sentiment Signal: Sell

Current Market Cap: A$381.6M

Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1